Clinical Trial

Aspirin Dosing in Pregnancy

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-19
Trial Details
NCT Number NCT07525635
Lead Sponsor NYU Langone Health
Conditions Preeclampsia Possible
Enrollment 30 participants
Start Date 2026-04-27
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-18